HLB Life Science Co Ltd
KOSDAQ:067630
HLB Life Science Co Ltd
Research & Development
HLB Life Science Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
Research & Development
-₩5.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-56%
|
|
|
C
|
Chorokbaem Healthcare Co Ltd
KRX:118000
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WSI Co Ltd
KOSDAQ:299170
|
Research & Development
-₩653.3m
|
CAGR 3-Years
-86%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
Wonik Co Ltd
KOSDAQ:032940
|
Research & Development
-₩1.5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
B
|
BlueMTec Co Ltd
KOSDAQ:439580
|
Research & Development
-₩1.3B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
HLB Life Science Co Ltd
Glance View
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
See Also
What is HLB Life Science Co Ltd's Research & Development?
Research & Development
-5.6B
KRW
Based on the financial report for Sep 30, 2025, HLB Life Science Co Ltd's Research & Development amounts to -5.6B KRW.
What is HLB Life Science Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-56%
Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for HLB Life Science Co Ltd have been -11% over the past three years , -38% over the past five years , and -56% over the past ten years .
